Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 4
2007 9
2008 12
2009 16
2010 28
2011 36
2012 46
2013 48
2014 71
2015 61
2016 54
2017 46
2018 53
2019 24
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

452 results
Results by year
Filters applied: . Clear all
Page 1
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Zheng SL, et al. JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024. JAMA. 2018. PMID: 29677303 Free PMC article. Review.
Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
Gargiulo P, Savarese G, D'Amore C, De Martino F, Lund LH, Marsico F, Dellegrottaglie S, Marciano C, Trimarco B, Perrone-Filardi P. Gargiulo P, et al. Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1081-1088. doi: 10.1016/j.numecd.2017.09.006. Epub 2017 Sep 28. Nutr Metab Cardiovasc Dis. 2017. PMID: 29113708 Review.
Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.
Sarraju A, Kim SH, Knowles JW. Sarraju A, et al. Curr Atheroscler Rep. 2016 Feb;18(2):7. doi: 10.1007/s11883-016-0558-5. Curr Atheroscler Rep. 2016. PMID: 26782825 Review.
452 results
Jump to page
Feedback